Kelman Lazarov Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 9.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,953 shares of the company’s stock after selling 395 shares during the period. Kelman Lazarov Inc.’s holdings in Johnson & Johnson were worth $698,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also modified their holdings of JNJ. Nordwand Advisors LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $785,273,000. Edmp Inc. raised its holdings in shares of Johnson & Johnson by 17,222.9% during the 4th quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after acquiring an additional 3,204,658 shares in the last quarter. Vanguard Group Inc. raised its holdings in Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after buying an additional 2,815,655 shares during the period. GQG Partners LLC raised its holdings in Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after buying an additional 2,547,378 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Johnson & Johnson by 37.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after buying an additional 1,805,632 shares during the period. 67.94% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Up 0.9 %
Shares of NYSE:JNJ opened at $165.03 on Wednesday. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $183.35. The stock has a market cap of $429.79 billion, a price-to-earnings ratio of 34.53, a PEG ratio of 2.78 and a beta of 0.53. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The business has a 50-day moving average price of $158.00 and a 200-day moving average price of $167.05.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.88%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is presently 94.56%.
Insider Transactions at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.20% of the company’s stock.
Analyst Ratings Changes
Several analysts recently weighed in on the company. StockNews.com assumed coverage on Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating on the stock. Morgan Stanley increased their target price on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. Guggenheim assumed coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price on the stock. Piper Sandler dropped their price target on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Finally, UBS Group assumed coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $173.00.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Do Bank Stocks Go Up When Interest Rates Rise?
- How to Invest in Vertical Farming Stocks
- Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
- Ecolab: Slow And Steady Wins The Race
- MGM’s Hot Hand Is All In For A Rally, After This Small Break
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
